PubMed HealthSearch

PubMed · 958869

[A simple flotation and McMaster method (author's transl)].

Abstract

A simple and hygienic flotation and McMaster method is described (cf. Fig. 1): The faeces sample (3-5 gm) is mixed with flotation fluid (40-60 ml) in a disposable plastic cup (cup I) and a circular piece of gauze, with a diameter equivalent to twice the height of the cup plus the diameter of its base, is placed over the cup. By a similar cup (cup II), with the bottom cut off and slits made in the side, the gauze is pressed down in cup I. By this procedure the faeces suspension will be filtered through the gauze and appear in cup II. After 10 minutes some drops after transferred from the surface of the filtrate to a slide by means of a test tube, which is dipped to the bottom of the filtrate and quickly moved over to the slide. The optimal procedure was worked out with faeces containing faeces containing eggs of Ostertagia ostertagi. Saturated sodium chloride with 50 g glucose per 100 ml was found to be a suitable flotation fluid for demonstrating eggs of commonly occurring parasites, e.g., trichostronglyids and ascarids. The described flotation technique is more efficacious than the one hitherto employed. The technique is usable also in connection with a McMaster method: 4 gm. faeces are suspended in 56 ml flotation fluid. Immediately following filtration, filtrate is transferred to a McMaster counting chamber by means of a Pasteur pipette.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S A Henriksen, K Aagaard. [A simple flotation and McMaster method (author's transl)].. https://pubmed.ncbi.nlm.nih.gov/958869/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Development and validation of a novel LC-MS/MS method for simultaneous quantification of fidaxomicin and metabolite (OP-1118) from feces for gut pharmacobiome studies.

Fidaxomicin is a first-line antibiotic for treating Clostridioides difficile infection. While it has low systemic absorption and reaches high colonic concentrations, it is hydrolyzed to a less active metabolite, OP-1118. Few studies have completely described critical experimental details of liquid chromatography-tandem mass spectrometry (LC-MS/MS) for quantifying fecal fidaxomicin and OP-1118. This study developed and validated a simple, fast, and sensitive LC-MS/MS method to quantify fidaxomicin and OP-1118 in human and mouse feces. This method simplified fecal sample preparation without the use of solid phase extraction and optimized LC-MS/MS parameters. A broad working range (0.3-1000 ng/ml) in both diluted human and murine fecal matrices was achieved with good intra- and inter-day accuracy (93-107%), precision (1-7%), and recovery (70-105%) as well as little IS-normalized matrix effects. This method was utilized to quantify fidaxomicin and OP-1118 in human and murine fecal samples. This novel method was simple, fast, sensitive, and accurate in analyzing fecal fidaxomicin and OP-1118 and could be deployed to facilitate gut pharmacobiome research.

Feces

Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer.

There is a high unmet need for early detection approaches for diffuse gastric cancer (DGC). We examined whether the stool proteome of mouse models of gastric cancer (GC) and individuals with hereditary diffuse gastric cancer (HDGC) have utility as biomarkers for early detection. Proteomic mass spectrometry of the stool of a genetically engineered mouse model driven by oncogenic KrasG12D and loss of p53 and Cdh1 in gastric parietal cells [known as Triple Conditional (TCON) mice] identified differentially abundant proteins compared with littermate controls. Immunoblot assays validated a panel of proteins, including actinin alpha 4 (ACTN4), N-acylsphingosine amidohydrolase 2 (ASAH2), dipeptidyl peptidase 4 (DPP4), and valosin-containing protein (VCP), as enriched in TCON stool compared with littermate control stool. Immunofluorescence analysis of these proteins in TCON stomach sections revealed increased protein expression compared with littermate controls. Proteomic mass spectrometry of stool obtained from patients with HDGC with CDH1 mutations identified increased expression of ASAH2, DPP4, VCP, lactotransferrin (LTF), and tropomyosin-2 relative to stool from healthy sex- and age-matched donors. Chemical inhibition of ASAH2 using C6 urea ceramide was toxic to GC cell lines and GC patient-derived organoids. This toxicity was reversed by adding downstream products of the S1P synthesis pathway, which suggested a dependency on ASAH2 activity in GC. An exploratory analysis of the HDGC stool microbiome identified features that correlated with patient tumors. Herein, we provide evidence supporting the potential of analyzing stool biomarkers for the early detection of DGC. Prevention Relevance: This study highlights a novel panel of stool protein biomarkers that correlate with the presence of DGC and has potential use as early detection to improve clinical outcomes.

Feces